13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839435
Total reported value
$1.1B
$1.1B
34 檔
18.3%
According to the latest 13F quarterly dataset, Octagon Capital Advisors LP managed an equity portfolio of $1.1B at the end of Q1 2025, spanning 34 distinct U.S. exchange-listed positions.
Octagon Capital Advisors LP executed strategic sector rebalancing during Q1 2025, establishing 30 new positions while fully exiting 30 holdings and trimming 0 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 9.31% | — | +8650.45% | |
| 2 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 8.86% | — | -30.36% | |
| 3 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 8.22% | -1.94% | +10.97% | |
| 4 | AVBP | Arrivent Biopharma Inc | Stock-Other | 7.37% | +1.12% | — | |
| 5 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 5.63% | -3.30% | EXIT | |
| 6 | TRVI | Trevi Therapeutics Inc | Stock-Other | 4.04% | -1.43% | — | |
| 7 | GOSS | Gossamer Bio Inc | Stock-Other | 3.91% | -0.17% | — | |
| 8 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.44% | -1.14% | — | |
| 9 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 3.42% | — | — | |
| 10 | COGT | Cogent Biosciences Inc | Stock-Other | 3.20% | -1.84% | — | |
| 11 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 3.06% | -3.23% | EXIT | |
| 12 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 2.88% | +1.55% | +2.39% | |
| 13 | NUVB | Nuvation Bio Inc | Stock-Other | 2.69% | — | -14.16% | |
| 14 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 2.67% | — | -61.97% | |
| 15 | TRML | Tourmaline Bio Inc | Stock-Other | 2.66% | — | — | |
| 16 | ✓ | Merus N V | Stock-Other | 2.51% | — | — | |
| 17 | PHVS | Pharvaris N.V. | Stock-Other | 2.34% | +0.90% | -1.05% | |
| 18 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.24% | — | — | |
| 19 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 2.15% | — | — | |
| 20 | ATYR | Atyr Pharma Inc | Stock-Other | 2.08% | — | +294.67% | |
| 21 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.05% | — | -32.58% | |
| 22 | VSTM | Verastem Inc | Stock-Other | 2.01% | — | — | |
| 23 | RGLS | Regulus Therapeutics Inc | Stock-Other | 1.57% | — | -4.37% | |
| 24 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.52% | — | — | |
| 25 | ABVX | Abivax Sa-adr | Stock-Other | 1.49% | +3.55% | — | |
| 26 | ERAS | Erasca Inc | Stock-Other | 1.36% | — | — | |
| 27 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.17% | — | -48.28% | |
| 28 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.15% | — | — | |
| 29 | ✓ | Stock-Other | 1.11% | — | — | ||
| 30 | MAZE | Maze Therapeutics Inc | Stock-Other | 1.00% | — | — | |
| 31 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.93% | -0.37% | EXIT | |
| 32 | KLRS | Kalaris Therapeutics Inc | Stock-Other | 0.75% | — | — | |
| 33 | NGNE | Neurogene Inc | Stock-Other | 0.69% | — | — | |
| 34 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.55% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ✓ | Merus N V | +1.6% | — | Add |
| 2 | GOSS | Gossamer Bio Inc | +1.5% | — | Add |
| 3 | TSHA | Taysha Gene Therapies Inc | +1.5% | +2.39% | Add |
| 4 | APLSUSD | Apellis Pharmaceuticals Inc | -7.6% | -30.36% | Add |
| 5 | NBP | Novabridge Biosciences | — | EXIT | Sold out |
| 6 | NUVB-WS | Nuvation Bio Inc -cw27 | — | NEW | New buy |
| 7 | DNTH | Dianthus Therapeutics Inc | — | NEW | New buy |
| 8 | AVBP | Arrivent Biopharma Inc | — | NEW | New buy |
| 9 | 260 | Centessa Pharmaceuticals-adr | — | NEW | New buy |
| 10 | CRISEUR | Curis Inc | — | EXIT | Sold out |
| 11 | BBIO | Bridgebio Pharma Inc | — | EXIT | Sold out |
| 12 | TRVI | Trevi Therapeutics Inc | — | NEW | New buy |
| 13 | RCUS | Arcus Biosciences Inc | — | EXIT | Sold out |
| 14 | FDMT | 4d Molecular Therapeutics In | — | EXIT | Sold out |
| 15 | ZLAB | Zai Lab Ltd-adr | — | EXIT | Sold out |
| 16 | CLDX | Celldex Therapeutics Inc | — | EXIT | Sold out |
| 17 | OCUL | Ocular Therapeutix Inc | — | NEW | New buy |
| 18 | BRD1EUR | Mind Medicine Mindmed Inc | — | NEW | New buy |
| 19 | COGT | Cogent Biosciences Inc | — | NEW | New buy |
| 20 | 4XC1 | Kalvista Pharmaceuticals Inc | — | NEW | New buy |
| 21 | VERA | Vera Therapeutics Inc | — | EXIT | Sold out |
| 22 | XLRN | Acceleron Pharma Inc | — | EXIT | Sold out |
| 23 | NUVB | Nuvation Bio Inc | — | NEW | New buy |
| 24 | VRNA | Verona Pharma PLC - Adr | — | NEW | New buy |
| 25 | TRML | Tourmaline Bio Inc | — | NEW | New buy |
| 26 | ARVN | Arvinas Inc | — | EXIT | Sold out |
| 27 | DYN | Dyne Therapeutics Inc | — | EXIT | Sold out |
| 28 | PHVS | Pharvaris N.V. | — | NEW | New buy |
| 29 | IPSC | Century Therapeutics Inc | — | EXIT | Sold out |
| 30 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 31 | SNDX | Syndax Pharmaceuticals Inc | — | NEW | New buy |
| 32 | RNAGBP | Avidity Biosciences Inc | — | EXIT | Sold out |
| 33 | ATYR | Atyr Pharma Inc | — | NEW | New buy |
| 34 | SRRK | Scholar Rock Holding CORP | — | NEW | New buy |
| 35 | VSTM | Verastem Inc | — | NEW | New buy |
| 36 | STOK | Stoke Therapeutics Inc | — | EXIT | Sold out |
| 37 | ✓ | — | EXIT | Sold out | |
| 38 | PMVP | Pmv Pharmaceuticals Inc | — | EXIT | Sold out |
| 39 | RGLS | Regulus Therapeutics Inc | — | NEW | New buy |
| 40 | SPRY | Ars Pharmaceuticals Inc | — | NEW | New buy |
| 41 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 42 | CNTB | Connect Biopharma Holdings Limited | — | EXIT | Sold out |
| 43 | ERAS | Erasca Inc | — | NEW | New buy |
| 44 | CRDF | Cardiff Oncology Inc | — | EXIT | Sold out |
| 45 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 46 | CRBP | Corbus Pharmaceuticals Holdi | — | NEW | New buy |
| 47 | ✓ | — | NEW | New buy | |
| 48 | ✓ | Ikena Oncology Inc | — | EXIT | Sold out |
| 49 | GLUE | Monte Rosa Therapeutics Inc | — | EXIT | Sold out |
| 50 | MAZE | Maze Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Octagon Capital Advisors LP reported a total U.S. public equity portfolio value of $1.1B across 34 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NUVB-WS, APLSUSD, DNTH) accounted for 18.3% of total reported equity market value during Q1 2025.
Top New Position Initiated
NUVB-WS
市值: $48.1M
Top Position Liquidated / Trimmed
NBP
前期市值: $79.2M
During Q1 2025, Octagon Capital Advisors LP's top holdings by market value included NUVB-WS (9.3%)、APLSUSD (8.9%)、DNTH (8.2%). The largest single position, NUVB-WS, represented 9.3% of total portfolio value.
In Q1 2025, Octagon Capital Advisors LP made 64 total portfolio adjustments, initiating 30 new buys, adding to 4 positions, trimming 0 holdings, and fully liquidating 30 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.